Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression
Article in Frontiers in Oncology (November 2022)
The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.
Article in Frontiers in Oncology (November 2022)
Article in ACS Pharmacology & Translational Science (July 2022)
Article in EBioMedicine (June 2022)